Search Our Trials

We are currently enrolling patients in the Clinical Trials listed below. New trials open regularly, and availability is subject to change. Search using key terms to find trials for which you may be eligible. Please contact us at (972) 566-3082 or email us at Referral@MaryCrowley.org to learn if one of our Clinical Trials is an option for you. We are here to answer your questions and will guide you through this process with HOPE and compassion for your unique journey.

Search Results

Trial Number
Mechanism of Action
Drug Classifications
Target
Conditions
Publications
24-05
BG-68501 is a CDK2 Inhibitor
CDK2 Inhibitor, Molecular Targeted Therapy
Solid Tumor

No

24-08
RMC-6291 is a tri-complex inhibitor of the active GTP-bound state of the mutated KRASG12C protein RMC-6236 is a RASMULTI(ON) inhibitor
Molecular Targeted Therapy, Small Molecule
KRASG12C
Solid Tumor

No

18-26
Adagrasib is a potent, highly selective and orally available small molecule inhibitor of a form of KRAS that harbors an oncogenic substitution mutation (G12C). mutation...
Small Molecule Inhibitor
KRAS G12C
Solid Tumor

Yes

20-08
TAK-676 is a synthetic cyclic dinucleotide (CDN) exhibiting highly selective binding and activation of STING pathway.
Immunotherapy, targeted
Not Required
Colorectal Cancer, Head and Neck Cancer, Solid Tumor

No

20-26
GDC-0077 – PI3K inhibitor Idasanutlin – MDM2 protein antagonist Alectinib – ALK kinase inhibitor Trastuzumab Emtansine – HER2 antibody-drug conjugate Ipatasertib – AKT inhibitor Atezolizumab...
Antibody Drug Conjugate, Monoclonal Antibody, Small Molecule, Targeted Therapy
[ROS1 fusion] tumors, [AKT1/2/3 mutant] tumors, [HER2 mutant] tumors, [MDM2-amplified, TP53 wild-type] tumors, [PIK3CA multiple mutant] tumors, [NTRK 1/2/3 fusion] tumors, [ALK fusion] tumors, TMB-high...
Solid Tumor

No

21-25
BI 1810631 is an EGFR wild type sparing, selective HER2 inhibitor with potent inhibitory activity on all oncogenic HER2 mutations including the HER2 YVMA insertion...
Targeted Therapy
HER2
Lung Cancer (NSCLC), Solid Tumor

Yes

21-41
ASP1570 is a small molecule immuno-oncology agent that is expected to act through the activation of immune cells in the tumor microenvironment.
Immunotherapy (Targeted), Small Molecule
Not Required
Lung Cancer (NSCLC), Skin Cancer/ Melanoma, Solid Tumor

No

22-02
IMP9064 is designed to inhibit the function of ATR, a component of the DNA damage repair system in all cells. Inhibition of DNA damage repair...
ATR inhibitor
PARP& ATR
Solid Tumor

No

22-05
MT-6402 may bind and kill both tumor and immune PD-L1 expressing cells in a manner consistent with SLTA mediated cellular cytotoxicity through ribosomal inactivation, independent...
6402 is a 514 amino acid cytotoxic fusion protein, comprised of 3 distinct polypeptide domains described here from N to C-terminus, targeting PD-L1
PD-L1
Head and Neck Cancer, Lung Cancer (NSCLC), Solid Tumor

No

22-07
IMM2902 is a bispecific antibody designed to bind to and block CD47, a cell surface protein that inhibits the immune response, and also bind to...
bispecific antibody
CD47, ERBB2
Breast Cancer, Esophageal Cancer, Gastric/GEJ Cancer, Solid Tumor

No

22-09
CS5001 is a highly differentiated Antibody Drug Conjugate targeting ROR1. ROR1 is expressed across a variety of cancers, and may play an important role in...
Antibody Drug Conjugate, Targeted Therapy
Not Required
Breast Cancer, Lymphoma, Lymphoma (Diffuse Large B-cell), Solid Tumor

No

22-13
UCT-03-008, CDK4/6 inhibitor, inhibits protein kinase from working and therefore, potentially stopping cancer cells to grow. Protein kinases are enzymes that are involved in the...
Small Molecule, Targeted Therapy
Not Required
Lung Cancer (NSCLC), Renal Cell Cancer, Solid Tumor

No

22-16
BP1001 a liposome-incorporated Grb2 antisense oligodeoxynucleotide binds directly to and blocks Grb2 mRNA, thereby preventing Grb2 protein synthesis, leading to inhibition of cell proliferation of...
Small Molecule
Not Required
Endometrial Cancer, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Solid Tumor

No

22-17
RMC-6236 inhibits the RAS(ON) state of multiple RAS variants both mutant and wild-type proteins.
Small Molecule
KRAS G12
Colorectal Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Solid Tumor

No

22-19
NUV-868 is a small molecule bromodomain 2 (BD2)-selective bromodomain and extra-terminal domain (BET) inhibitor. The BET family of proteins have critical biological functions and are...
Small Molecule
Not Required
Breast Cancer, Colorectal Cancer, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Pancreatic Cancer, Solid Tumor

No

22-20
PEEL-223 is a small molecule topoisomerase 1 (TOP1) inhibitor, which may lead to inhibiting the repair of single-strand DNA breaks, DNA replication, and tumor cell...
Small Molecule (Targeted)
Not Required
Solid Tumor

No

22-23
ART0380 selectively targets and inhibits ATR activity and blocks the downstream phosphorylation of the serine/threonine protein kinase checkpoint kinase 1 (CHK1). This prevents ATR-mediated signaling,...
Small Molecule, Targeted Therapy
ATM Gene Alterations likely to predict loss of ATM protein
Solid Tumor

No

22-35
MRT-2359 induces degradation of GSPT1 and associated downregulation of MYC transcription factors and their transcriptional outputs, which may lead to preferential anti-proliferative activity in MYC-driven...
Small Molecule, Targeted Therapy
Not Required
Lung Cancer (NSCLC), Lung Cancer (SCLC), Lymphoma (Diffuse Large B-cell), Solid Tumor

No

22-36
E7386 inhibits beta-catenin and prevents the interaction of beta-catenin with its transcriptional coactivator, CREB (cAMP response element-binding) binding protein (CBP). This prevents binding of beta-catenin/CBP...
Small Molecule
Not Required
Colorectal Cancer, Endometrial Cancer, Hepatocellular Cancer, Solid Tumor

No

22-39
JAB-2485 is a small molecule Aurora A inhibitor. Inhibition of Aurora A activity at the cellular level, induces apoptosis and inhibits tumor growth.
JAB-2485 is a small molecule Aurora A inhibitor
Not Required
Solid Tumor

No

23-01
Small molecule inhibitor of USP1
Molecular Targeted Therapy, Small Molecule
Monotherapy – Tumor Biopsy Cohort: have the following deleterious homologous recombination repair (HRR+) tumor mutations: BRCA1, BRCA2, PALB2, RAD51, RAD51B, RAD51C, RAD51D, BARD1, BRIP1, FANCA,...
Ovarian/ Peritoneal/ Fallopian Tube Cancer, Solid Tumor

No

23-02
anti-GREM1 monoclonal antibody
Immunotherapy, Monoclonal Antibody
Not Required
Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric/GEJ Cancer, Lung Cancer (NSCLC), Prostate Cancer, Solid Tumor

No

23-04
ASP1002 is anti-CLDN4 and anti-CD137 bispecific antibody
Bispecific Antibodies
Not Required
Solid Tumor

No

23-05
KT-253 is an MDM2 degrader
Molecular Targeted Therapy
Not Required
Lymphoma, Solid Tumor

No

23-06
STX-478 is a PI3Kα small molecule inhibitor.
Molecular Targeted Therapy, Small Molecule
PI3Kα
Breast Cancer, Solid Tumor

No

23-09
EO-3021 is an anti-CLDN18.2 antibody drug conjugate.
Antibody Drug Conjugate
CLDN18.2
Esophageal Cancer, Gastric/GEJ Cancer, Lung Cancer (NSCLC), Ovarian/ Peritoneal/ Fallopian Tube Cancer, Pancreatic Cancer, Solid Tumor

No

23-10
ART6043 is a Polθ inhibitor
Molecular Targeted Therapy, Small Molecule
*Genetic lesions known to cause loss of function of known DDR genes *Hormone-receptor status, breast cancer gene (BRCA) mutation
Breast Cancer, Solid Tumor

No

23-15
HF158K1 is a HER2-targeting antibody liposome
Antibody Drug Conjugate, Immunotherapy, targeted
HER-2 positive or HER-2 low expression
Solid Tumor

No

23-16
INCB099280 is a PD-L1 inhibitor. Adagrasib is a KRAS inhibitor (G12C).
Immunotherapy, Molecular Targeted Therapy, Small Molecule Immunotherapy
Not Required
Colorectal Cancer, Lung Cancer (NSCLC), Solid Tumor

No

23-17
EGFR x HER3 bispecific antibody-drug conjugate
Antibody Drug Conjugate, Bispecific Antibodies
Not Required
Lung Cancer (NSCLC), Solid Tumor

No

23-18
LCB84 is an anti-TROP2 ADC
Antibody Drug Conjugate
Not Required
Anal Cancer, Breast Cancer, Colorectal Cancer, Endometrial Cancer, Gastric/GEJ Cancer, Lung Cancer (NSCLC), osteosarcoma, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Pancreatic Cancer, Solid Tumor

No

23-19
RMC-9805 is a KRAS G12D inhibitor
Molecular Targeted Therapy, Small Molecule (Targeted)
KRASG12D
Solid Tumor

No

23-22
GSK4524101 is a POLQ inhibitor
Molecular Targeted Therapy, Small Molecule
Not Required
Solid Tumor

No

23-23
BH3120 is a PD-L1 x 4-1BB Bispecific Monoclonal Antibody
Bispecific Antibodies, Immunotherapy
PD-L1 positive expression
Solid Tumor

No

23-24
FB849 is a HPK1 inhibitor
Immunotherapy, Small Molecule
Not Required
Breast Cancer, Colorectal Cancer, Solid Tumor

No

23-28
AT-1965 is a CMTR2 inhibitor
Molecular Targeted Therapy, Small Molecule (Targeted)
Not Required
Breast Cancer, Solid Tumor

No

JIT-20210023
n/a
n/a
CDKN2A null, MTAP null
Solid Tumor

No

JIT-ENV-ONC-101
ENV- 101, a potent Hedgehog (Hh) pathway inhibitor
n/a
PTCH1 loss of function
Solid Tumor

No

JIT-TSC-007
n/a
Molecular Targeted Therapy
Inactivating Alterations in TSC1 or TSC2
Solid Tumor

No

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.